non prescription glp-1 use tripled among non-diabetics, reaching $5.8B in 2022 GLP-1 Agonists For Obesity In

The rate of non-fatal stroke, non-fatal MI, and hospitalization for HF did not show significant differences (78)

But GLP-1 subcutaneous injections should cause minimal discomfort when done correctly

GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives

injection battle heating up between Lilly and Novo, what doctors are seeing with oral prescriptions, and why cost remains the elephant in the room for a market headed toward $100 billion

VK2735, same dual agonist in pill form

The most commonly reported side effects in retatrutide clinical trials have been gastrointestinal, including nausea, vomiting, diarrhea, constipation, abdominal discomfort, and decreased appetite